ARQ 751
Showing 1 - 25 of 89
Cancer, Solid Tumors Trial in United States (Vevorisertib, Fulvestrant, Paclitaxel)
Atopic Dermatitis Eczema Trial in Canada, United States (ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%)
Recruiting
- Atopic Dermatitis Eczema
- ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
-
Birmingham, Alabama
- +91 more
Jan 26, 2023
Atopic Dermatitis Eczema Trial in Canada, United States (ARQ-151 Active, ARQ-151 Vehicle)
Recruiting
- Atopic Dermatitis Eczema
- ARQ-151 Active
- ARQ-151 Vehicle
-
Birmingham, Alabama
- +75 more
Jan 26, 2023
Chronic Plaque Psoriasis Trial in Canada, United States (ARQ-151 0.3% cream, ARQ-151 vehicle cream)
Completed
- Chronic Plaque Psoriasis
- ARQ-151 0.3% cream
- ARQ-151 vehicle cream
-
Scottsdale, Arizona
- +38 more
Dec 5, 2022
Chronic Plaque Psoriasis Trial in Canada, United States (Topical roflumilast)
Enrolling by invitation
- Chronic Plaque Psoriasis
- Topical roflumilast
-
Beverly Hills, California
- +68 more
Nov 9, 2022
Plaque Psoriasis Trial in Worldwide (ARQ-154 foam 0.3%, ARQ-154 vehicle foam)
Completed
- Plaque Psoriasis
- Roflumilast foam 0.3%
- Vehicle foam
-
Rogers, Arkansas
- +46 more
Oct 24, 2022
Seborrheic Dermatitis Trial in Canada, United States (ARQ-154 - Active, ARQ-154 Vehicle)
Completed
- Seborrheic Dermatitis
- ARQ-154 - Active
- ARQ-154 Vehicle
-
Scottsdale, Arizona
- +52 more
Aug 4, 2022
Seborrheic Dermatitis Trial in Canada, United States (ARQ-154 foam 0.3%, ARQ-154 vehicle foam)
Completed
- Seborrheic Dermatitis
- ARQ-154 foam 0.3%
- ARQ-154 vehicle foam
-
Fremont, California
- +23 more
Aug 4, 2022
Vitiligo Trial in United States (ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment)
Terminated
- Vitiligo
- ARQ-252 cream 0.3%
- +3 more
-
San Diego, California
- +4 more
Aug 4, 2022
Atopic Dermatitis Eczema Trial in Canada, United States (ARQ-151 Active, ARQ-151 Vehicle)
Active, not recruiting
- Atopic Dermatitis Eczema
- ARQ-151 Active
- ARQ-151 Vehicle
-
Montgomery, Alabama
- +48 more
Aug 10, 2022
Atopic Dermatitis Eczema Trial in Canada, United States (ARQ-151 Active, ARQ-151 Vehicle Cream)
Recruiting
- Atopic Dermatitis Eczema
- ARQ-151 Active
- ARQ-151 Vehicle Cream
-
Birmingham, Alabama
- +52 more
Aug 4, 2022
Scalp Psoriasis Trial in Canada, United States (ARQ-154 Foam 0.3%, ARQ-154 Vehicle)
Completed
- Scalp Psoriasis
- ARQ-154 Foam 0.3%
- ARQ-154 Vehicle
-
Scottsdale, Arizona
- +48 more
Aug 4, 2022
Psoriasis, Plaque Psoriasis Trial in Canada, Dominican Republic, United States (ARQ-151 cream 0.3%)
Completed
- Psoriasis
- Plaque Psoriasis
- ARQ-151 cream 0.3%
-
Mountain Brook, Alabama
- +17 more
Aug 2, 2022
Psoriasis, Plaque Psoriasis Trial in Canada, Dominican Republic, United States (ARQ-151 cream 0.3%)
Completed
- Psoriasis
- Plaque Psoriasis
- ARQ-151 cream 0.3%
-
Mountain Brook, Alabama
- +16 more
Aug 2, 2022
Chronic Plaque Psoriasis Trial in Canada, United States (ARQ-151 0.3% cream, ARQ-151 vehicle cream)
Completed
- Chronic Plaque Psoriasis
- Roflumilast 0.3% cream
- Vehicle Cream
-
Encinitas, California
- +39 more
Dec 5, 2022
Plaque Psoriasis Trial in Canada, United States (Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream)
Completed
- Plaque Psoriasis
- Roflumilast Cream 0.3%
- +2 more
-
Beverly Hills, California
- +29 more
Aug 31, 2022
Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders Trial (ARQ 092)
No longer available
- Proteus Syndrome
- +2 more
- ARQ 092
- (no location specified)
Jul 31, 2021
Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia Trial in United States (ABT-751, Dexamethasone,
Terminated
- Recurrent Pediatric ALL
- +3 more
- ABT-751
- +7 more
-
Los Angeles, California
- +4 more
Feb 22, 2021
Sarcoma, Stomach Tumors, Tumors Trial run by the NCI (Pazopanib, ARQ 197)
Completed
- Sarcoma
- +2 more
- Pazopanib
- ARQ 197
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Jun 23, 2021
Colorectal Cancer Metastatic, C-met Overexpression Trial in Rozzano (Tivantinib (ARQ197))
Completed
- Colorectal Cancer Metastatic
- C-met Overexpression
- Tivantinib (ARQ197)
-
Rozzano, Milano, ItalyIstituto Clinico Humanitas
Sep 8, 2022
Obese Trial (high flow nasal oxygen device (HFNO))
Not yet recruiting
- Obese
- high flow nasal oxygen device (HFNO)
- (no location specified)
Jun 2, 2021